Literature DB >> 17657655

IV levetiracetam in the management of non-convulsive status epilepticus.

Muhammad U Farooq1, Bharath Naravetla, Arshad Majid, Rishi Gupta, Joseph J Pysh, Mounzer Y Kassab.   

Abstract

INTRODUCTION: Status epilepticus (SE) is a medical emergency requiring prompt treatment to try to limit mortality and improve outcome. So far, newer antiepileptic drugs (AED) have not assumed a noticeable role in the treatment of SE. This may be in part due to the lack of IV forms for the newer AEDs. The IV form of Levetiracetam (IV-LEV) has recently become available and has a potential role in the treatment of SE. METHODS AND
RESULTS: We report two cases of non-convulsive SE that responded favorably to IV-LEV. The first patient is an 83-year-old male with a history of complex partial seizure disorder who presented with impaired consciousness. The second patient is an 82-year-old male with history of old left middle cerebral artery ischemic infarction, who presented with confusion. Both patients were found to have a non-convulsive status epilepticus on electroencephalography (EEG) and treated with IV-LEV. In both cases, electrographic SE stopped with marked clinical improvement. Both patients tolerated the medication well and no significant side effects occurred.
CONCLUSION: IV-LEV may have a potential role in the treatment of non-convulsive status epileptics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657655     DOI: 10.1007/s12028-007-0022-z

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  7 in total

Review 1.  Neuromodulation with levetiracetam and vagus nerve stimulation in experimental animal models of epilepsy.

Authors:  Stefanie Dedeurwaerdere; Kristl Vonck; Veerle De Herdt; Liesbeth Waterschoot; Tim De Smedt; Robrecht Raedt; Tine Wyckhuys; Benjamin Legros; Peter Van Hese; Koen Van Laere; Jean Delbeke; Wytse Wadman; Paul Boon
Journal:  Acta Neurol Belg       Date:  2006-06       Impact factor: 2.396

2.  Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.

Authors:  Steven Ramael; Agnès Daoust; Christian Otoul; Nathalie Toublanc; Mona Troenaru; Zhihong Sarah Lu; Armel Stockis
Journal:  Epilepsia       Date:  2006-07       Impact factor: 5.864

3.  Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy.

Authors:  W Löscher; D Hönack; C Rundfeldt
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

4.  The use of levetiracetam in refractory status epilepticus.

Authors:  Nitin C Patel; Ivan R Landan; Jeffrey Levin; Jerzy Szaflarski; Andrew N Wilner
Journal:  Seizure       Date:  2006-01-19       Impact factor: 3.184

5.  Levetiracetam as a treatment option in non-convulsive status epilepticus.

Authors:  Sven Rupprecht; Kerstin Franke; Sabine Fitzek; Otto W Witte; Georg Hagemann
Journal:  Epilepsy Res       Date:  2006-12-08       Impact factor: 3.045

6.  Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes.

Authors:  Andrea O Rossetti; Edward B Bromfield
Journal:  Eur Neurol       Date:  2005-08-10       Impact factor: 1.710

7.  Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.

Authors:  Michel Gillard; Pierre Chatelain; Bruno Fuks
Journal:  Eur J Pharmacol       Date:  2006-03-10       Impact factor: 4.432

  7 in total
  8 in total

1.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Safety and efficacy of levetiracetam for critically ill patients with seizures.

Authors:  Karen M Nau; Gavin D Divertie; Alden K Valentino; William D Freeman
Journal:  Neurocrit Care       Date:  2009-01-29       Impact factor: 3.210

3.  Intravenous levetiracetam as treatment for status epilepticus.

Authors:  Sascha Berning; Frank Boesebeck; Andreas van Baalen; Christoph Kellinghaus
Journal:  J Neurol       Date:  2009-05-15       Impact factor: 4.849

4.  Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures.

Authors:  Nicholas S Abend; Heather M Monk; Daniel J Licht; Dennis J Dlugos
Journal:  Pediatr Crit Care Med       Date:  2009-07       Impact factor: 3.624

5.  Status epilepticus: current treatment strategies.

Authors:  Edward M Manno
Journal:  Neurohospitalist       Date:  2011-01

Review 6.  Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy.

Authors:  Sima I Patel; Angela K Birnbaum; James C Cloyd; Ilo E Leppik
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

7.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

8.  Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients - What Do We Know so Far?

Authors:  Hae Won Shin; Robin Davis
Journal:  Front Neurol       Date:  2013-08-05       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.